Efficacy of AI-Assisted Colonoscopy for Screening Colorectal Neoplasia (AI-COLOSCREEN) (NCT07307547) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Efficacy of AI-Assisted Colonoscopy for Screening Colorectal Neoplasia (AI-COLOSCREEN)
China3,342 participantsStarted 2026-04
Plain-language summary
This study is a multi-center, randomized controlled trial designed to evaluate whether an artificial intelligence (AI) system can assist endoscopists to improve the detection rate of colorectal adenomas and cancers during colonoscopy compared to standard colonoscopy. Early screening and diagnosis are key to reducing the burden of colorectal cancer, but current colonoscopy has limitations, including the risk of missed lesions. This trial aims to determine if AI can enhance screening quality and diagnostic accuracy.
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age between 18 and 75 years, inclusive.
✓. Scheduled for a screening, diagnostic, or surveillance colonoscopy.
✓. Able to understand the study protocol and provide written informed consent.
Exclusion criteria
✕. Known contraindications to colonoscopy or biopsy.
✕. Personal history of colorectal cancer, inflammatory bowel disease (IBD), or previous colorectal surgery.
✕. Known or suspected colorectal polyposis syndrome (e.g., Familial Adenomatous Polyposis - FAP).
✕. Patients with active colorectal bleeding, bowel obstruction, or toxic megacolon.
✕. Women who are pregnant, planning to become pregnant, or are breastfeeding.
✕. Participation in another interventional clinical trial within the 30 days prior to enrollment.
✕
What they're measuring
1
Adenoma Detection Rate (ADR)
Timeframe: From the day of the procedure up to 14 days post-procedure.